Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II rec...
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
- Associated Therapies
- -
A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM
- Conditions
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2011-06-15
- Lead Sponsor
- LaborMed Pharma S.A.
- Target Recruit Count
- 56
- Registration Number
- NCT00980187
- Locations
- 🇷🇴
Cardiology, University and Emergency Hospital, Bucharest, Romania
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 154
- Registration Number
- NCT00976495
- Locations
- 🇺🇸
Prism Research, St. Paul, Minnesota, United States
🇺🇸Memorial Hospital Of Rhode Island, Pawtucket, Rhode Island, United States
🇳🇱Local Institution, Groningen, Netherlands
Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2011-10-26
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 124
- Registration Number
- NCT00935805
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
- First Posted Date
- 2009-06-23
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 894
- Registration Number
- NCT00926289
- Locations
- 🇺🇸
502.550.01007 Boehringer Ingelheim Investigational Site, Greensboro, North Carolina, United States
🇨🇳502.550.86002 Boehringer Ingelheim Investigational Site, Shanghai, China
🇨🇳502.550.86007 Boehringer Ingelheim Investigational Site, Tianjin, China
A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2009-10-08
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 34
- Registration Number
- NCT00923533
Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 24
- Registration Number
- NCT00887510
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
A Translational Approach to Gitelman Syndrome
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 8
- Registration Number
- NCT00822107
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-01-13
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 144
- Registration Number
- NCT00821574
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2011-03-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 532
- Registration Number
- NCT00797316
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1254
- Registration Number
- NCT00797862
- Locations
- 🇻🇪
Investigative Site, Caracas, Venezuela
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.